GFI1B mutation causes autosomal dominant gray platelet syndrome

Affiliations

¹ The Canadian Pharmacogenomic Network for Drug Safety (CPNDS), Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, V5Z4H4, Canada.

Comment

F Aminkeng. Clin Genet. 2014 Jun.

. 2014 Jun;85(6):534-5.

doi: 10.1111/cge.12380. Epub 2014 Apr 9.

¹ The Canadian Pharmacogenomic Network for Drug Safety (CPNDS), Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, V5Z4H4, Canada.

No abstract available

Comment on

A dominant-negative GFI1B mutation in the gray platelet syndrome.
Monteferrario D, Bolar NA, Marneth AE, Hebeda KM, Bergevoet SM, Veenstra H, Laros-van Gorkom BA, MacKenzie MA, Khandanpour C, Botezatu L, Fransen E, Van Camp G, Duijnhouwer AL, Salemink S, Willemsen B, Huls G, Preijers F, Van Heerde W, Jansen JH, Kempers MJ, Loeys BL, Van Laer L, Van der Reijden BA. Monteferrario D, et al. N Engl J Med. 2014 Jan 16;370(3):245-53. doi: 10.1056/NEJMoa1308130. Epub 2013 Dec 10. N Engl J Med. 2014. PMID: 24325358